Insider Monkey42d agoneutral
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline GrowthNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
104last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
24/7 Wall St.43d agoneutral
How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield TrapSimply Wall St.43d agoneutral
What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?Stocktwits44d agoneutral
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not PipelinesMotley Fool44d agobullish
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool44d agoneutral
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?24/7 Wall St.44d agoneutral
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next DecadeMotley Fool45d agobullish
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?Motley Fool45d agobullish
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?Insider Monkey46d agoneutral
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPOInsider Monkey47d agobullish
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still MattersBioPharma Dive47d agoneutral
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide